
FDA advisory panel approves AcelRx’s opioid pain drug Dsuvia
pharmafile | October 15, 2018 | News story | Sales and Marketing | FDA, approval, comittee, opioids
An FDA advisory panel voted 10 to 3 to recommend the approval of AcelRx Pharmaceuticals’ opioid pain drug Dsuvia (sufentanil) to manage moderate-to-severe acute pain in adults in medically supervised settings.
The go-ahead has come after the federal agency questioned the drugs superiority and raised concerns surrounding the medication’s small pill size which could lead to accidental use.
Chief medical officer Pamela Palmer commented: “We look forward to continued collaboration with the FDA on the application as we believe Dsuvia represents an important non-invasive acute pain management option with potential to significantly improve the current standard of care.”
The decision comes after a Phase III trial conducted in 2016 suggtested that the therapy was associated with a 35% reduction in pain intensity in patients who visited the emergency room for moderate to severe pain caused by injury or trauma.
Louis Goss
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …




